A Phase 1 interventional study of Palbociclib and Letrozole in Advanced Breast Cancer, sponsored by Pfizer. Completed at 7 sites in China. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by Pfizer · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies testing palbociclib in Breast Neoplasms — 19 open to participants now, 43 under way, 9 of them phase 3. palbociclib · Breast Neoplasms.
Among the 111 studies testing palbociclib in Breast Neoplasms, this one is the 97th largest by enrollment, is one of 13 that started in 2015, is one of 14 in phase 1, and was the 23rd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →19 of the 111 studies testing palbociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18+
American Society of Clinical Oncology · Sites in United States
Ages 60+
Region Örebro County · Sites in Finland, Greece, Italy and 3 more countries
Ages 70+
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Germany
Ages 18+ · Women only
Northwestern University · Sites in United States
Ages 18+
By country, each count listing its studies:
palbociclib: first FDA approval 2015 (IBRANCE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, palbociclib is the treatment under test here. Read study by study →
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 68 · Phase 3 21 · Phase 4 5
First in 2008; this study’s year is marked. 13 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 111 interventional studies. Of the 54 that completed or were terminated, 27 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 111 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 94th largest by enrollment of the 121 interventional ones that give a count, is one of 3 that started in 2015, is one of 37 in phase 1, and was the 86th registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
13 of the studies testing palbociclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820830Phase 3ETOP IBCSG Partners FoundationPalbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | 2026-12 |
| NCT02605486Memorial Sloan Kettering Cancer CenterPalbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) | 2026-11 |
| NCT02738866Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPalbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor | 2026-12 |
| NCT07130643Xinhong Wu, PhDEfficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer | 2026-12-20 |
| NCT03573648Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNeoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer | 2026-12-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 111 studies testing palbociclib in Breast Neoplasms, from their registry updates:
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
As part of the global clinical development program for Palbociclib, studies are planned in cancer patients in China. An assessment of Palbociclib pharmacokinetics in Chinese patients, as required by the Chinese Health Authorities, is therefore warranted. In addition, safety and efficacy will be also evaluated.
The single and multiple 125 mg oral dose pharmacokinetics of Palbociclib will be characterized.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
ER(+), (-), adult (ages 18-65 years, inclusive) Chinese women with proven diagnosis of adenocarcinoma of the breast with evidence locoregionally recurrent or disease not amenable to resection or radiation therapy with curative intent and for whom chemotherapy is not clinically indicated.
a. Postmenopausal women: i. Prior bilateral surgical oophorectomy; or ii. Medically confirmed post-menopausal status defined as spontaneous cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause b. Documentation of or cytologically confirmed diagnosis of: i. ER(+) breast cancer. c. Documentation of HER2(-) breast cancer. d. Previously untreated with any systemic anti cancer therapy for their locoregionally recurrent or metastatic ER+ disease.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination therapy of palbociclib and letrozole
Drug: Palbociclib · Drug: Letrozole
125 mg orally once daily with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle
2.5 mg , orally once daily (continuously)
Single-dose Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) for Palbociclib
Cmax of palbociclib in the single-dose part (lead-in phase) was observed directly from data.
Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Single-dose PK: Time to Reach Maximum Plasma Concentration (Tmax) for Palbociclib
Tmax for palbociclib in the single-dose part (lead-in phase) was observed directly from data as time of first occurrence.
Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Single-dose PK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to the Time 10 Hours (AUC10) for Palbociclib
AUC10 for palbociclib in the single-dose part (lead-in phase) was obtained by linear/log trapezoidal method.
Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, and 10 hours post dose
Single-dose PK: AUC From Time 0 to the Time 24 Hours (AUC24) for Palbociclib
AUC24 is AUCtau, where the dosing interval (tau) is 24 hours. AUC24 in the single-dose part (lead-in phase) for palbociclib was obtained by linear/log trapezoidal method.
Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, and 24 hours post dose
Single-dose PK: AUC From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Palbociclib
AUClast for palbociclib in the single-dose part (lead-in phase) was obtained by linear/log trapezoidal method.
Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Single-dose PK: AUC From Time 0 Extrapolated to Infinite Time (AUCinf) for Palbociclib
AUCinf for palbociclib in the single-dose part (lead-in phase) was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the rate constant for terminal phase obtained by linear regression of the log-linear concentration-time curve.
Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Single-dose PK: Rate Constant for Terminal Phase (Kel) for Palbociclib
Kel for palbociclib in the single-dose part (lead-in phase) was obtained by linear regression of the log-linear concentration-time curve.
Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Single-dose PK: Mean Residence Time (MRT) for Palbociclib
MRT for palbociclib in the single-dose part (lead-in phase) was calculated as AUMCinf/AUCinf, where AUMCinf was area under the first moment curve from time 0 to infinity.
Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Single-dose PK: Terminal Half-Life (t1/2) for Palbociclib
t1/2 for palbociclib in the single-dose part (lead-in phase) was calculated as Loge(2)/kel.
Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Single-dose PK: Apparent Oral Clearance (CL/F) for Palbociclib
CL/F for palbociclib in the single-dose part (lead-in phase) was calculated as Dose/AUCinf.
Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Single-dose PK: Apparent Volume of Distribution (Vz/F) for Palbociclib
Vz/F for palbociclib in the single-dose part (lead-in phase) was calculated as Dose/(AUCinf \* kel).
Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Multiple-dose PK: Maximum Plasma Concentration at Steady State (Css,Max) for Palbociclib
Css,max of palbociclib in the multiple-dose part (Cycle 1) was observed directly from data.
Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24, 48, 72, 96, 120 hours post dose on Day 21
Multiple-dose PK: Minimum Plasma Concentration at Steady State (Css,Min) for Palbociclib
Css,min of palbociclib in the multiple-dose part (Cycle 1) was observed directly from data.
Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24, 48, 72, 96, 120 hours post dose on Day 21
Multiple-dose PK: AUC Within a Dosing Interval of Tau (=24 Hours) at Steady State (AUCss,Tau) for Palbociclib
AUCss,tau of palbociclib in the multiple-dose part (Cycle 1) was determined by linear/log trapezoidal method.
Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, and 24 hours post dose on Day 21
Multiple-dose PK: Average Plasma Concentration at Steady State (Css,av) for Palbociclib
Css,av of palbociclib in the multiple-dose part (Cycle 1) was calculated as AUCss,tau/tau, where tau was 24 hours.
Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, and 24 hours post dose on Day 21
Multiple-dose PK: Time to Reach Maximum Plasma Concentration at Steady State (Tss,Max) for Palbociclib
Tss,max of palbociclib in the multiple-dose part (Cycle 1) was observed directly from data as time of first occurrence within tau (=24 hours) at steady state.
Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, and 24 hours post dose on Day 21
Multiple-dose PK: Vz/F for Palbociclib
Vz/F of palbociclib in the multiple-dose part (Cycle 1) was calculated as Dose/(AUCss,tau \* kel), where AUCss,tau was the AUC within a dosing interval of tau (=24 hours) at steady state and kel was the terminal phase rate constant following multiple-dose calculated by a linear regression of the log-linear concentration-time curve.
Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24, 48, 72, 96, 120 hours post dose on Day 21
Multiple-dose PK: t1/2 for Palbociclib
t1/2 of palbociclib in the multiple-dose part (Cycle 1) was calculated as ln (2)/kel, where kel was the terminal phase rate constant following multiple-dose calculated by a linear regression of the log-linear concentration-time curve.
Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24, 48, 72, 96, 120 hours post dose on Day 21
Multiple-dose PK: CL/F for Palbociclib
CL/F of palbociclib in the multiple-dose part (Cycle 1) was calculated as Dose/AUCss,tau, where AUCss,tau was the AUC within a dosing interval of tau (=24 hours) at steady state.
Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, and 24 hours post dose on Day 21
Multiple-dose PK: Peak to Trough Fluctuation at Steady State (PTF) for Palbociclib
PTF of palbociclib in the multiple-dose part (Cycle 1) was determined as (Css,max - Css,min)/Css,av. Css,max and Css,min were observed directly from data while Css,av was calculated as AUCss,tau/tau, where tau was 24 hours.
Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24, 48, 72, 96, 120 hours post dose on Day 21
Observed Accumulation Ratio (Rac) for Palbociclib
Rac of palbociclib was determined as AUCss,tau/AUCsd,tau, where AUCss,tau (tau=24 hours) was from multiple-dose part (Cycle 1) and AUCsd,tau was AUC24 from single-dose part (lead-in phase).
Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, and 24 hours post dose; Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, and 24 hours post dose on Day 21
Steady State Accumulation Ratio (Rss) for Palbociclib
Rss of palbociclib was calculated as AUCss,tau/AUCinf, where AUCss,tau (tau=24 hours) was from multiple-dose part (Cycle 1) and AUCinf was from single-dose part (lead-in phase).
Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose; Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24 hours post dose on Day 21
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity on or after the first dose of investigational product administration. AEs included both SAEs and non-serious AEs. Causality to study treatment was determined by the investigator.
Time frame: From first dose of study medication up to 28 days after last dose of study medication (up to maximum of 475 weeks, maximum treatment exposure = 471 weeks)
Number of Participants With Treatment-Emergent AEs by Maximum National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity on or after the first dose of investigational product administration. AEs included both SAEs and non-serious AEs. Causality to study treatment was determined by the investigator. AEs were graded by NCI CTCAE version 4.0: Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE.
Time frame: From first dose of study medication up to 28 days after last dose of study medication (up to maximum of 475 weeks, maximum treatment exposure = 471 weeks)
Number of Participants With Laboratory Test Abnormalities
The number of participants with the following laboratory test abnormalities meeting any of the Grades 1 to 4 criteria per the NCI CTCAE (version 4.0) is summarized: anemia, lymphopenia, neutropenia, platelet count decreased, white blood cell (WBC) decreased, alanine aminotransferase (ALT) increased, alkaline phosphatase increased, aspartate aminotransferase (AST) increased, bilirubin (total) increased, creatinine increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, and hyponatremia. Grade 1=mild, Grade 2=moderate, Grade 3=severe and Grade 4=life-threatening. One participant might had more than 1 laboratory test abnormality.
Time frame: From first dose of study medication up to 28 days after last dose of study medication (up to maximum of 475 weeks, maximum treatment exposure = 471 weeks)
Number of Participants Meeting the Categorical Summarization Criteria for QTcF and QTcB Parameters
QT interval (time from electrocardiogram \[ECG\] Q wave and the end of the T wave corresponding to electrical systole) corrected for heart rate using Fridericia's formula was QTcF and QT interval corrected for heart rate using Bazett's formula was QTcB. Categorical summarization criteria for QTcF and QTcB were as follows: 1) maximum absolute value of \<450 milliseconds (msec), \>=450 to \<=480 msec, \>=481 to \<=500 msec, or \>=500 msec; 2) maximum increase from baseline of \<30 msec, \>=30 to \<60 msec, or \>=60 msec. One participant could be reported under more than 1 categorical summarization criteria for QTcF and QTcB Parameters.
Time frame: From first dose of study medication up to 28 days after last dose of study medication (up to maximum of 475 weeks, maximum treatment exposure = 471 weeks)
Progression-Free Survival (PFS)
PFS was defined as the time from Cycle 1 Day 1 (C1D1) to date of first documentation of disease progression (PD) or death due to any cause, whichever occurred first. Documentation of progression was by objective disease assessment as defined by the Response Evaluation Criteria in Solid Tumor (RECIST) (version 1.1). PD was defined as a \>=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 millimeter (mm); or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new unequivocal malignant lesions. Median PFS was estimated using the Kaplan-Meier method.
Time frame: From C1D1 to date of first documentation of PD or death due to any cause, whichever occurred first (up to maximum of 471 weeks of treatment exposure)
Percentage of Participants Achieving Objective Response (Objective Response Rate [ORR])
ORR was the percentage of participants with an objective response (complete response \[CR\] or partial response \[PR\]). Per RECIST (version 1.1). CR: complete disappearance of all target lesions except nodal disease or disappearance of all non-target lesions and normalization of tumor marker levels. All target nodes/lymph nodes must decrease to normal size (\<10 mm short axis); PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions (short diameter=sum for target nodes; longest diameter=sum for all other target lesions). PD: 20% increase in sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions.
Time frame: From C1D1 until disease progression or death due to any cause, whichever occurred first (up to maximum of 471 weeks of treatment exposure)
Percentage of Participants Achieving Disease Control (Disease Control Rate [DCR])
Disease control (DC) = CR, PR or stable disease (SD) \>= 24 weeks according to RECIST version 1.1 recorded from C1D1 until disease progression or death due to any cause. CR: complete disappearance of all target lesions except nodal disease or disappearance of all non-target lesions and normalization of tumor marker levels. All target nodes/lymph nodes must decrease to normal size (\<10 mm short axis); PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions (short diameter=sum for target nodes; longest diameter=sum for all other target lesions). SD: Does not qualify for CR, PR or progression. PD: 20% increase in sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm or appearance of new unequivocal malignant lesions.
Time frame: From C1D1 until disease progression or death due to any cause, whichever occurred first (up to maximum of 471 weeks of treatment exposure)
Duration of Response
Duration of response was the time from first documentation of CR or PR to date of first documentation of PD or death for the participants with an objective response (CR or PR). Per RECIST (version 1.1). CR: complete disappearance of all target lesions except nodal disease or disappearance of all non-target lesions and normalization of tumor marker levels. All target nodes/lymph nodes must decrease to normal size (\<10 mm short axis); PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions (short diameter=sum for target nodes; longest diameter=sum for all other target lesions). PD: 20% increase in sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions. Kaplan-Meier method was used.
Time frame: From first documentation of CR or PR to date of first documentation of objective progression or death, whichever occurred first (up to maximum of 471 weeks of treatment exposure)
1-Year PFS Probability
PFS was defined as the time from C1D1 to date of first documentation of PD or death due to any cause, whichever occurred first. Documentation of progression was by objective disease assessment as defined by the RECIST (version 1.1). PD was defined as a \>=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 millimeter (mm); or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new unequivocal malignant lesions. One-year PFS probability was defined as the probability (expressed as percentage) of PFS at 1 year after C1D1. PFS probability was determined using the Kaplan-Meier method.
Time frame: 1 year
Trough Plasma Concentration of Letrozole
Plasma samples were analyzed for letrozole concentrations using a validated, sensitive and specific high-performance liquid chromatography tandem mass spectrometric (HPLC/MS/MS) method.
Time frame: pre-dose of Cycle 1 Days 19, 20, 21 and Cycle 2 Day 1
Ratio Over Baseline for Skin Biomarker Phosphorylated Retinoblastoma Protein (pRb) Expression
The pRb was one of the skin biomarkers and samples were assayed using immunohistochemistry (IHC) method. Ratio over baseline was calculated by dividing the H-score value for pRb at each specified time point by baseline value. The H-score value, which could range from 0 to 300 (strongest expression) with higher score representing stronger expression, was calculated from the total of each individual intensity of staining (0 \[negative\], 1+ \[weak\], 2+ \[moderate\], 3+ \[strong\]) multiplied by the percentages of cells (0 to 100) that represented that staining.
Time frame: Baseline (Day -1), lead-in phase Days 1 and 2, Cycle 1 Days 21, 22, 23, 24, 25, 26
Ratio Over Baseline for Skin Biomarker Ki67 Expression
The Ki67 was one of the skin biomarkers and samples were assayed using IHC method. Ratio over baseline was calculated by dividing the percentage of Ki67 positive cells at each specified time point by baseline value.
Time frame: Baseline (Day -1), lead-in phase Days 1 and 2, Cycle 1 Days 21, 22, 23, 24, 25, 26
Ratio Over Baseline for Thymidine Kinase (TK) Concentration
Blood samples were collected to provide serum for the assessments of TK activity. The concentrations of TK were determined using enzyme-linked immunosorbent assay (ELISA) method. Ratio of serum TK concentration at each specified time point over baseline value was presented.
Time frame: Baseline (Day -1 pre-dose), lead-in phase Day 1 (4, 8, 10, 24, 72, 120 hours post dose), Cycle 1 Day 21 (4, 8, 10, 24, 72, 96, 120 hours post dose), Cycle 2 Day 1 pre-dose
| Milestone | Palbociclib + Letrozole |
|---|---|
| Started | 26 |
| Completed | 0 |
| Not completed | 26 |
| Withdrew: Global deterioration of health status | 1 |
| Withdrew: Objective progression or relapse | 20 |
| Withdrew: Other | 2 |
| Withdrew: Participant refused continued treatment for reason other than adverse event | 3 |
Cmax of palbociclib in the single-dose part (lead-in phase) was observed directly from data.
| nanograms per milliliter (ng/mL) | Palbociclib + Letrozole |
|---|---|
| Single-dose Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) for Palbociclib | 82.14 ± 25 |
Tmax for palbociclib in the single-dose part (lead-in phase) was observed directly from data as time of first occurrence.
| hours | Palbociclib + Letrozole |
|---|---|
| Single-dose PK: Time to Reach Maximum Plasma Concentration (Tmax) for Palbociclib | 7.94 (3.97 to 10.0) |
AUC10 for palbociclib in the single-dose part (lead-in phase) was obtained by linear/log trapezoidal method.
| nanograms*hour per milliliter (ng*hr/mL) | Palbociclib + Letrozole |
|---|---|
| Single-dose PK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to the Time 10 Hours (AUC10) for Palbociclib | 498.3 ± 28 |
AUC24 is AUCtau, where the dosing interval (tau) is 24 hours. AUC24 in the single-dose part (lead-in phase) for palbociclib was obtained by linear/log trapezoidal method.
| ng*hr/mL | Palbociclib + Letrozole |
|---|---|
| Single-dose PK: AUC From Time 0 to the Time 24 Hours (AUC24) for Palbociclib | 1217 ± 22 |
AUClast for palbociclib in the single-dose part (lead-in phase) was obtained by linear/log trapezoidal method.
| ng*hr/mL | Palbociclib + Letrozole |
|---|---|
| Single-dose PK: AUC From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Palbociclib | 2308 ± 27 |
AUCinf for palbociclib in the single-dose part (lead-in phase) was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the rate constant for terminal phase obtained by linear regression of the log-linear concentration-time curve.
| ng*hr/mL | Palbociclib + Letrozole |
|---|---|
| Single-dose PK: AUC From Time 0 Extrapolated to Infinite Time (AUCinf) for Palbociclib | 2386 ± 27 |
Kel for palbociclib in the single-dose part (lead-in phase) was obtained by linear regression of the log-linear concentration-time curve.
| per hour | Palbociclib + Letrozole |
|---|---|
| Single-dose PK: Rate Constant for Terminal Phase (Kel) for Palbociclib | 0.03006 ± 0.00420 |
MRT for palbociclib in the single-dose part (lead-in phase) was calculated as AUMCinf/AUCinf, where AUMCinf was area under the first moment curve from time 0 to infinity.
| hours | Palbociclib + Letrozole |
|---|---|
| Single-dose PK: Mean Residence Time (MRT) for Palbociclib | 34.42 ± 4.32 |
t1/2 for palbociclib in the single-dose part (lead-in phase) was calculated as Loge(2)/kel.
| hours | Palbociclib + Letrozole |
|---|---|
| Single-dose PK: Terminal Half-Life (t1/2) for Palbociclib | 23.46 ± 3.14 |
CL/F for palbociclib in the single-dose part (lead-in phase) was calculated as Dose/AUCinf.
| liters per hour (L/hr) | Palbociclib + Letrozole |
|---|---|
| Single-dose PK: Apparent Oral Clearance (CL/F) for Palbociclib | 52.40 ± 27 |
Vz/F for palbociclib in the single-dose part (lead-in phase) was calculated as Dose/(AUCinf \* kel).
| liters | Palbociclib + Letrozole |
|---|---|
| Single-dose PK: Apparent Volume of Distribution (Vz/F) for Palbociclib | 1758 ± 21 |
Css,max of palbociclib in the multiple-dose part (Cycle 1) was observed directly from data.
| ng/mL | Palbociclib + Letrozole |
|---|---|
| Multiple-dose PK: Maximum Plasma Concentration at Steady State (Css,Max) for Palbociclib | 139.7 ± 28 |
Css,min of palbociclib in the multiple-dose part (Cycle 1) was observed directly from data.
| ng/mL | Palbociclib + Letrozole |
|---|---|
| Multiple-dose PK: Minimum Plasma Concentration at Steady State (Css,Min) for Palbociclib | 67.55 ± 46 |
AUCss,tau of palbociclib in the multiple-dose part (Cycle 1) was determined by linear/log trapezoidal method.
| ng*hr/mL | Palbociclib + Letrozole |
|---|---|
| Multiple-dose PK: AUC Within a Dosing Interval of Tau (=24 Hours) at Steady State (AUCss,Tau) for Palbociclib | 2501 ± 29 |
Css,av of palbociclib in the multiple-dose part (Cycle 1) was calculated as AUCss,tau/tau, where tau was 24 hours.
| ng/mL | Palbociclib + Letrozole |
|---|---|
| Multiple-dose PK: Average Plasma Concentration at Steady State (Css,av) for Palbociclib | 104.2 ± 29 |
Tss,max of palbociclib in the multiple-dose part (Cycle 1) was observed directly from data as time of first occurrence within tau (=24 hours) at steady state.
| hours | Palbociclib + Letrozole |
|---|---|
| Multiple-dose PK: Time to Reach Maximum Plasma Concentration at Steady State (Tss,Max) for Palbociclib | 6.05 (3.97 to 10.0) |
Vz/F of palbociclib in the multiple-dose part (Cycle 1) was calculated as Dose/(AUCss,tau \* kel), where AUCss,tau was the AUC within a dosing interval of tau (=24 hours) at steady state and kel was the terminal phase rate constant following multiple-dose calculated by a linear regression of the log-linear concentration-time curve.
| Liters | Palbociclib + Letrozole |
|---|---|
| Multiple-dose PK: Vz/F for Palbociclib | 1910 ± 29 |
t1/2 of palbociclib in the multiple-dose part (Cycle 1) was calculated as ln (2)/kel, where kel was the terminal phase rate constant following multiple-dose calculated by a linear regression of the log-linear concentration-time curve.
| hours | Palbociclib + Letrozole |
|---|---|
| Multiple-dose PK: t1/2 for Palbociclib | 27.26 ± 3.19 |
CL/F of palbociclib in the multiple-dose part (Cycle 1) was calculated as Dose/AUCss,tau, where AUCss,tau was the AUC within a dosing interval of tau (=24 hours) at steady state.
| L/hr | Palbociclib + Letrozole |
|---|---|
| Multiple-dose PK: CL/F for Palbociclib | 49.97 ± 29 |
PTF of palbociclib in the multiple-dose part (Cycle 1) was determined as (Css,max - Css,min)/Css,av. Css,max and Css,min were observed directly from data while Css,av was calculated as AUCss,tau/tau, where tau was 24 hours.
| ratio | Palbociclib + Letrozole |
|---|---|
| Multiple-dose PK: Peak to Trough Fluctuation at Steady State (PTF) for Palbociclib | 0.6652 ± 27 |
Rac of palbociclib was determined as AUCss,tau/AUCsd,tau, where AUCss,tau (tau=24 hours) was from multiple-dose part (Cycle 1) and AUCsd,tau was AUC24 from single-dose part (lead-in phase).
| ratio | Palbociclib + Letrozole |
|---|---|
| Observed Accumulation Ratio (Rac) for Palbociclib | 2.042 ± 27 |
Rss of palbociclib was calculated as AUCss,tau/AUCinf, where AUCss,tau (tau=24 hours) was from multiple-dose part (Cycle 1) and AUCinf was from single-dose part (lead-in phase).
| ratio | Palbociclib + Letrozole |
|---|---|
| Steady State Accumulation Ratio (Rss) for Palbociclib | 1.036 ± 26 |
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity on or after the first dose of investigational product administration. AEs included both SAEs and non-serious AEs. Causality to study treatment was determined by the investigator.
| Participants | Palbociclib + Letrozole |
|---|---|
| Treatment-emergent AEs (all causalities) | 26 |
| Treatment-emergent AEs (treatment-related) | 26 |
| Treatment-emergent SAEs (all causalities) | 4 |
| Treatment-emergent SAEs (treatment-related) | 1 |
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity on or after the first dose of investigational product administration. AEs included both SAEs and non-serious AEs. Causality to study treatment was determined by the investigator. AEs were graded by NCI CTCAE version 4.0: Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE.
| Participants | Palbociclib + Letrozole |
|---|---|
| Grade 1 | 0 |
| Grade 2 | 5 |
| Grade 3 | 16 |
| Grade 4 | 5 |
| Grade 5 | 0 |
The number of participants with the following laboratory test abnormalities meeting any of the Grades 1 to 4 criteria per the NCI CTCAE (version 4.0) is summarized: anemia, lymphopenia, neutropenia, platelet count decreased, white blood cell (WBC) decreased, alanine aminotransferase (ALT) increased, alkaline phosphatase increased, aspartate aminotransferase (AST) increased, bilirubin (total) increased, creatinine increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, and hyponatremia. Grade 1=mild, Grade 2=moderate, Grade 3=severe and Grade 4=life-threatening. One participant might had more than 1 laboratory test abnormality.
| Participants | Palbociclib + Letrozole |
|---|---|
| Anemia | 23 |
| Lymphopenia | 19 |
| Neutropenia | 26 |
| Platelet count decreased | 20 |
| WBC decreased | 25 |
| ALT increased | 11 |
| Alkaline phosphatase increased | 12 |
| AST increased | 18 |
| Bilirubin (total) increased | 4 |
| Creatinine increased | 25 |
| Hypercalcemia | 1 |
| Hyperglycemia | 10 |
| Hyperkalemia | 0 |
| Hypermagnesemia | 2 |
| Hypernatremia | 6 |
| Hypoalbuminemia | 11 |
| Hypocalcemia | 11 |
| Hypoglycemia | 0 |
| Hypokalemia | 6 |
| Hypomagnesemia | 5 |
| Hyponatremia | 6 |
QT interval (time from electrocardiogram \[ECG\] Q wave and the end of the T wave corresponding to electrical systole) corrected for heart rate using Fridericia's formula was QTcF and QT interval corrected for heart rate using Bazett's formula was QTcB. Categorical summarization criteria for QTcF and QTcB were as follows: 1) maximum absolute value of \<450 milliseconds (msec), \>=450 to \<=480 msec, \>=481 to \<=500 msec, or \>=500 msec; 2) maximum increase from baseline of \<30 msec, \>=30 to \<60 msec, or \>=60 msec. One participant could be reported under more than 1 categorical summarization criteria for QTcF and QTcB Parameters.
| Participants | Palbociclib + Letrozole |
|---|---|
| Maximum QTcF <450 msec | 21 |
| Maximum QTcF >=450 to <=480 msec | 4 |
| Maximum QTcF >=481 to <=500 msec | 1 |
| Maximum QTcF >500 msec | 0 |
| Maximum increase in QTcF <30 msec | 17 |
| Maximum increase in QTcF >=30 to <60 msec | 9 |
| Maximum increase in QTcF >=60 msec | 0 |
| Maximum QTcB <450 msec | 9 |
| Maximum QTcB >=450 to <=480 msec | 16 |
| Maximum QTcB >=481 to <=500 msec | 0 |
| Maximum QTcB >500 msec | 1 |
| Maximum increase in QTcB <30 msec | 16 |
| Maximum increase in QTcB >=30 to <60 msec | 9 |
| Maximum increase in QTcB >=60 msec | 1 |
PFS was defined as the time from Cycle 1 Day 1 (C1D1) to date of first documentation of disease progression (PD) or death due to any cause, whichever occurred first. Documentation of progression was by objective disease assessment as defined by the Response Evaluation Criteria in Solid Tumor (RECIST) (version 1.1). PD was defined as a \>=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 millimeter (mm); or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new unequivocal malignant lesions. Median PFS was estimated using the Kaplan-Meier method.
| Months | Palbociclib + Letrozole |
|---|---|
| Progression-Free Survival (PFS) | 18.6 (6.5 to 27.7) |
ORR was the percentage of participants with an objective response (complete response \[CR\] or partial response \[PR\]). Per RECIST (version 1.1). CR: complete disappearance of all target lesions except nodal disease or disappearance of all non-target lesions and normalization of tumor marker levels. All target nodes/lymph nodes must decrease to normal size (\<10 mm short axis); PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions (short diameter=sum for target nodes; longest diameter=sum for all other target lesions). PD: 20% increase in sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions.
| Percentage of participants | Palbociclib + Letrozole |
|---|---|
| Percentage of Participants Achieving Objective Response (Objective Response Rate [ORR]) | 19.2 (6.6 to 39.4) |
Disease control (DC) = CR, PR or stable disease (SD) \>= 24 weeks according to RECIST version 1.1 recorded from C1D1 until disease progression or death due to any cause. CR: complete disappearance of all target lesions except nodal disease or disappearance of all non-target lesions and normalization of tumor marker levels. All target nodes/lymph nodes must decrease to normal size (\<10 mm short axis); PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions (short diameter=sum for target nodes; longest diameter=sum for all other target lesions). SD: Does not qualify for CR, PR or progression. PD: 20% increase in sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm or appearance of new unequivocal malignant lesions.
| Percentage of participants | Palbociclib + Letrozole |
|---|---|
| Percentage of Participants Achieving Disease Control (Disease Control Rate [DCR]) | 65.4 (44.3 to 82.8) |
Duration of response was the time from first documentation of CR or PR to date of first documentation of PD or death for the participants with an objective response (CR or PR). Per RECIST (version 1.1). CR: complete disappearance of all target lesions except nodal disease or disappearance of all non-target lesions and normalization of tumor marker levels. All target nodes/lymph nodes must decrease to normal size (\<10 mm short axis); PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions (short diameter=sum for target nodes; longest diameter=sum for all other target lesions). PD: 20% increase in sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions. Kaplan-Meier method was used.
| Months | Palbociclib + Letrozole |
|---|---|
| Duration of Response | 25.1 (8.3 to NA) |
PFS was defined as the time from C1D1 to date of first documentation of PD or death due to any cause, whichever occurred first. Documentation of progression was by objective disease assessment as defined by the RECIST (version 1.1). PD was defined as a \>=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 millimeter (mm); or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new unequivocal malignant lesions. One-year PFS probability was defined as the probability (expressed as percentage) of PFS at 1 year after C1D1. PFS probability was determined using the Kaplan-Meier method.
| Percentage probability | Palbociclib + Letrozole |
|---|---|
| 1-Year PFS Probability | 57.5 (35.3 to 74.5) |
Plasma samples were analyzed for letrozole concentrations using a validated, sensitive and specific high-performance liquid chromatography tandem mass spectrometric (HPLC/MS/MS) method.
| nanograms per milliliter (ng/mL) | Palbociclib + Letrozole |
|---|---|
| Cycle 1 Day 19 pre-dose | 83.70 (30.8 to 134) |
| Cycle 1 Day 20 pre-dose | 83.85 (41.4 to 141) |
| Cycle 1 Day 21 pre-dose | 85.30 (38.2 to 134) |
| Cycle 2 Day 1 pre-dose | 97.40 (48.8 to 282) |
The pRb was one of the skin biomarkers and samples were assayed using immunohistochemistry (IHC) method. Ratio over baseline was calculated by dividing the H-score value for pRb at each specified time point by baseline value. The H-score value, which could range from 0 to 300 (strongest expression) with higher score representing stronger expression, was calculated from the total of each individual intensity of staining (0 \[negative\], 1+ \[weak\], 2+ \[moderate\], 3+ \[strong\]) multiplied by the percentages of cells (0 to 100) that represented that staining.
| ratio | Palbociclib + Letrozole |
|---|---|
| Lead-in phase Day 1 | 0.644 ± 56.34 |
| Lead-in phase Day 2 | 0.523 ± 92.28 |
| Cycle 1 Day 21 | 0.535 ± 108.77 |
| Cycle 1 Day 22 | 0.773 ± 57.77 |
| Cycle 1 Day 23 | 0.799 ± 91.59 |
| Cycle 1 Day 24 | 1.493 ± 103.46 |
| Cycle 1 Day 25 | 1.165 ± 99.39 |
| Cycle 1 Day 26 | 2.164 ± 87.80 |
The Ki67 was one of the skin biomarkers and samples were assayed using IHC method. Ratio over baseline was calculated by dividing the percentage of Ki67 positive cells at each specified time point by baseline value.
| ratio | Palbociclib + Letrozole |
|---|---|
| Lead-in phase Day 1 | 0.985 ± 42.32 |
| Lead-in phase Day 2 | 0.868 ± 64.99 |
| Cycle 1 Day 21 | 0.495 ± 107.24 |
| Cycle 1 Day 22 | 0.408 ± 135.34 |
| Cycle 1 Day 23 | 0.599 ± 80.00 |
| Cycle 1 Day 24 | 0.832 ± 42.34 |
| Cycle 1 Day 25 | 0.920 ± 85.52 |
| Cycle 1 Day 26 | 1.301 ± 61.26 |
Blood samples were collected to provide serum for the assessments of TK activity. The concentrations of TK were determined using enzyme-linked immunosorbent assay (ELISA) method. Ratio of serum TK concentration at each specified time point over baseline value was presented.
| ratio | Palbociclib + Letrozole |
|---|---|
| Lead-in phase Day 1, 4 hours post dose | 0.780 ± 44.69 |
| Lead-in phase Day 1, 8 hours post dose | 0.774 ± 43.65 |
| Lead-in phase Day 1, 10 hours post dose | 0.733 ± 49.67 |
| Lead-in phase Day 1, 24 hours post dose | 0.702 ± 48.93 |
| Lead-in phase Day 1, 72 hours post dose | 0.530 ± 50.14 |
| Lead-in phase Day 1, 120 hours post dose | 0.598 ± 74.40 |
| Cycle 1 Day 21, 4 hours post dose | 0.260 ± 172.41 |
| Cycle 1 Day 21, 8 hours post dose | 0.236 ± 191.22 |
| Cycle 1 Day 21, 10 hours post dose | 0.236 ± 187.02 |
| Cycle 1 Day 21, 24 hours post dose | 0.247 ± 164.37 |
| Cycle 1 Day 21, 48 hours post dose | 0.244 ± 166.61 |
| Cycle 1 Day 21, 72 hours post dose | 0.268 ± 163.67 |
| Cycle 1 Day 21, 96 hours post dose | 0.292 ± 176.92 |
| Cycle 1 Day 21, 120 hours post dose | 0.455 ± 334.32 |
| Cycle 2 Day 1, pre-dose | 1.069 ± 248.43 |
Collected over From first dose of study medication up to 28 days after last dose of study medication (up to maximum of 475 weeks, maximum treatment exposure = 471 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Palbociclib + Letrozole | 0/26 (0%) | 4/26 (15.4%) | 26/26 (100%) |
| Event | Palbociclib + Letrozole |
|---|---|
| Drug-induced liver injuryHepatobiliary disorders | 1/26 |
| PneumoniaInfections and infestations | 1/26 |
| AbscessInfections and infestations | 1/26 |
| OsteomyelitisInfections and infestations | 1/26 |
| Pneumonia viralInfections and infestations | 1/26 |
| Event | Palbociclib + Letrozole |
|---|---|
| Neutrophil count decreasedInvestigations | 16/26 |
| Platelet count decreasedInvestigations | 15/26 |
| White blood cell count decreasedInvestigations | 15/26 |
| AnaemiaBlood and lymphatic system disorders | 13/26 |
| LeukopeniaBlood and lymphatic system disorders | 11/26 |
| Aspartate aminotransferase increasedInvestigations | 11/26 |
| NeutropeniaBlood and lymphatic system disorders | 10/26 |
| Alanine aminotransferase increasedInvestigations | 10/26 |
| Haemoglobin decreasedInvestigations | 6/26 |
| FatigueGeneral disorders | 5/26 |
All enrolled participants who received at least 1 dose of study medication.
| Age, Continuous(years) | Palbociclib + Letrozole |
|---|---|
| Mean | 50.8 ± 7.6 |
| Sex: Female, Male(Participants) | Palbociclib + Letrozole |
|---|---|
| Female | 26 |
| Male | 0 |
| Race/Ethnicity, Customized(Participants) | Palbociclib + Letrozole |
|---|---|
| Asian | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Sep 2015 to primary completion in Jul 2018, 34 months.
Results were first posted in Jul 2019, 11 months after primary completion.
Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 34 months is below that.
Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palbociclib